Merus NV
(FRA:2GH)
€
48.8
1.4 (2.95%)
Market Cap: 3.27 Bil
Enterprise Value: 2.97 Bil
PE Ratio: 0
PB Ratio: 8.88
GF Score: 57/100 Merus NV at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023 / 08:40PM GMT
Release Date Price:
€16.7
(+13.61%)
Andy Berens
SVB Securities - Analyst
Good morning, everyone. I'm Andy Berens, Senior Biotech Analyst at SVB Securities and Head of Targeted Oncology. Thanks for joining us on day three of our 12th Annual Global Healthcare Conference. We're very excited this session to have Bill Lundberg, the CEO of Merus, to join us. Thank you, Bill, for spending some time with us.
Bill Lundberg
Merus N.V. - President, CEO, Principal Financial Officer & Executive Director
Thank you, Andy, and thanks to the entire SVB team for the opportunity to speak today and the continued support you've shown Merus.
Andy Berens
SVB Securities - Analyst
Okay. Why don't we start with a general question? Just a little overview about the company for those that may be new to the story.
Bill Lundberg
Merus N.V. - President, CEO, Principal Financial Officer & Executive Director
Yes, sure. I'm happy to share a couple of slides as well that might frame out the story if that would be helpful.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot